News

Inbank Reports Impressive Growth in Financial Performance

Inbank Reports Impressive Growth in Financial Performance

Inbank's Stellar Financial Performance in Recent Quarters

Inbank has achieved significant milestones in its Q2 2025 financial results, showcasing dynamic growth and resilience in a fluctuating market. The bank reported a remarkable originated volume of 196 million euros, marking a 15% increase from the previous year. Although consolidated net profit saw a slight decline to 3.6 million euros compared to the same period last year, the profit for the first half of 2025 rose 5% to 8.1 million euros, highlighting a robust performance.

Growing Revenues and Key Financial Metrics

Inbank's total net income for the second quarter reached 20.7 million euros, an increase of 8.4% year-on-year. The income derived from core activities, which excludes financial and other ancillary income, saw a healthy 15.3% growth, rising to 21.1 million euros, up from 18.3 million euros from the prior year. Operating expenses also increased to 11.6 million euros, reflecting a 7.1% rise. This cost management has allowed Inbank to improve its cost/income ratio down to 55.9% for this quarter.

Additionally, the strong performance of Inbank was significantly driven by a high demand for green financing products, particularly in Poland, and record direct lending activities across all markets the bank operates in.

Impressive Growth in Specific Segments

A key highlight of both Q2 2025 and the first half of the year was the impressive growth in green financing, which surged 86% year-on-year, reaching 36.9 million euros. Moreover, direct lending increased by a remarkable 44%, amounting to 32.1 million euros. The merchant solutions segment contributed substantially to Inbank’s overall performance, achieving sales of 66.5 million euros, a 3% increase. Car financing exhibited signs of resilience with a total volume of 47.1 million euros, despite being slightly 10% lower compared to last year. Rental services showed a significant rebound, delivering 13.1 million euros, which is 25% higher compared to the previous year.

Asset and Loan Portfolio Expansion

The loan and rental portfolio at Inbank amassed to 1.21 billion euros, reflecting an 11.2% growth year-on-year, while the customer deposit portfolio expanded by 4.9% to 1.23 billion euros. Notably, Inbank's total assets as of the end of Q2 stood at 1.5 billion euros, showcasing a steady 5% growth annually.

Strategic Focus and Market Share Enhancement

Priit Põldoja, the CEO of Inbank, commented on the results by emphasizing their strategic growth approach, which maintains a disciplined outlook. He noted that while Inbank reached a record-high originated volume, continuous exploration of new niches, particularly in the €50 billion Polish consumer finance market, is crucial for sustainable profitability. He pointed out that Inbank has successfully extended its market share across the Baltics, achieving a noteworthy 20.3% share in consumer lending in Estonia. As interest rates decrease, margins are likely to improve, fostering further growth opportunities.

Product Diversification and New Offerings

Inbank is not only expanding geographically but is also focused on enhancing its suite of product offerings. Recently, the bank introduced payment protection insurance in Latvia and Lithuania, completing its coverage in the Baltic region. This aims to bolster the range of fee-based products available to its vast customer base, which is a strategic priority for the organization.

Strengthening Governance and Leadership

Inbank has also been proactive in enhancing its governance structure by appointing Erkki Raasuke as the independent Chairman of the Supervisory Board and adding new board members, including Isabel Faragalli, a debt capital markets expert, and Sergei Anikin, a seasoned technology leader. This strengthened board is expected to facilitate Inbank's strategic growth in embedded finance across Europe.

Key Financial Indicators Summary

As of June 30, 2025:
Total assets: 1.50 billion euros
Loan and rental portfolio: 1.21 billion euros
Customer deposits: 1.23 billion euros
Total equity: 156 million euros
Net profit: 3.6 million euros
Return on equity: 9.3%

Inbank continues to be a rising player in the financial technology space with its unique embedded finance platform, linking merchants, consumers, and financial institutions. With a strong emphasis on eco-friendly financing products and a solid growth trajectory, Inbank is poised to capitalize on future market opportunities.

For more information regarding Inbank, please reach out to:\
Styv Solovjov
AS Inbank
Head of Investor Relations
+372 5645 9738
styv.solovjov@inbank.ee

Frequently Asked Questions

What are Inbank's financial results for Q2 2025?

In Q2 2025, Inbank recorded 196 million euros in originated volume and a net profit of 3.6 million euros.

How did Inbank's income from core activities perform in Q2?

Inbank's income from core activities grew by 15.3% to 21.1 million euros in Q2 2025.

What strategic areas is Inbank focusing on for growth?

Inbank aims to expand its market share in the Baltic region and explore opportunities in the Polish consumer finance market.

Who are some of the new members of Inbank's Supervisory Board?

The new members include Erkki Raasuke as independent Chairman, Isabel Faragalli, and Sergei Anikin.

What is Inbank's total asset value as of June 30, 2025?

As of June 30, 2025, Inbank's total assets amounted to 1.5 billion euros.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 13

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 18

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 19

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 24

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 20

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 24

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 15

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 19

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 19

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Inbank Reports Impressive Growth in Financial Performance

Updated Category News Views 237

Inbank's Stellar Financial Performance in Recent Quarters Inbank has achieved significant milestones in its Q2 2025 financial results, showcasing dynamic growth and resilience in a fluctuating market. The bank reported a remarkable originated volume of 196 million euros, marking a 15% increase from the previous year. Although consolidated net profit saw a slight decline...

Continue Reading
Navient Elects Edward Bramson as Chair After Shareholder Meeting

Updated Category News Views 164

Navient's Annual Meeting Marks a New Chapter HERNDON, Va. - Recently, Navient (Nasdaq: NAVI) convened its Annual Meeting of Shareholders, setting the stage for significant leadership changes within the company. This year, shareholders engaged actively, voting to approve three pivotal proposals outlined by the board of directors. This included the election of seven new...

Continue Reading
Annexon Secures $75 Million in Public Stock Offering

Updated Category News Views 184

Overview of Annexon's Recent Public Offering Annexon, Inc. (NASDAQ: ANNX), a pioneering biopharmaceutical firm, recently announced the successful pricing of its public offering aimed at raising $75 million. This exciting event took place as the company continues to push forward with its mission to address neuroinflammation and related diseases, facilitating groundbreaking...

Continue Reading
Werner Enterprises Set for Key Investment Conferences This Year

Updated Category News Views 310

Werner Enterprises is Poised for Investment Conference Engagements Werner Enterprises, Inc. (Nasdaq: WERN), a well-known name in transportation and logistics, is preparing to participate in several significant investment conferences. These events present a fantastic opportunity for the company to share insights about its growth strategies and market position. Upcoming...

Continue Reading
Cunard Achieves Unprecedented Booking Milestones in 2024

Updated Category News Views 156

Record-Breaking Booking Success for Cunard Cunard has recently announced remarkable booking figures for the year 2024, driven by a stellar year and the eagerly awaited introduction of its ship, Queen Anne. This significant increase has resulted in an astonishing 73,000 more guest reservations from January to October compared to the same timeframe in the previous year,...

Continue Reading